CIK 0001472091
- Non-accelerated filer
- Smaller reporting company
PDS Biotechnology Corp
Sign in to watch- Ticker
- PDSB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 264231384
- Phone
- +1 800-208-3343
- Business address
- 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
- Former names
- Edge Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2015-10-06 | BARER SOL J Director | Conversion · Series C-2 Convertible Preferred Stock | −144,086 | 0 | ||
| 2015-10-06 | LOUGHLIN JAMES J Director | Conversion | +12,261 | 12,261 | ||
| 2015-10-06 | LOUGHLIN JAMES J Director | Purchase | +7,000 | $11.00 | $77K | 19,261 |
| 2015-10-06 | LOUGHLIN JAMES J Director | Other acquisition | +364 | $8.60 | $3K | 19,625 |
| 2015-10-06 | LOUGHLIN JAMES J Director | Conversion · Series C-2 Convertible Preferred Stock | −16,774 | 0 | ||
| 2015-10-06 | Spiegel Robert J. Director | Conversion | +23,579 | 23,579 | ||
| 2015-10-06 | Spiegel Robert J. Director | Conversion | +10,533 | 34,112 | ||
| 2015-10-06 | Spiegel Robert J. Director | Purchase | +3,000 | $11.00 | $33K | 37,112 |
| 2015-10-06 | Spiegel Robert J. Director | Other acquisition | +1,549 | $7.91 | $12K | 38,661 |
| 2015-10-06 | Spiegel Robert J. Director | Conversion · Series C-1 Convertible Preferred Stock | −32,258 | 0 | ||
| 2015-10-06 | Spiegel Robert J. Director | Conversion · Series C-2 Convertible Preferred Stock | −14,409 | 0 | ||
| 2015-10-06 | HEALY JAMES Director | Conversion | +1,807,703 | 1,807,703 | ||
| 2015-10-06 | HEALY JAMES Director | Purchase | +450,000 | $11.00 | $5.0M | 2,257,703 |
| 2015-10-06 | HEALY JAMES Director | Other acquisition | +53,665 | $8.60 | $462K | 2,311,368 |
| 2015-10-06 | HEALY JAMES Director | Conversion · Series C-2 Convertible Preferred Stock | −2,473,118 | 0 | ||
| 2015-10-06 | Macdonald R. Loch Chief Scientific Officer | Conversion | +18,274 | 566,480 | ||
| 2015-10-06 | Macdonald R. Loch Chief Scientific Officer | Conversion | +3,928 | 570,408 | ||
| 2015-10-06 | Macdonald R. Loch Chief Scientific Officer | Other acquisition | +194 | $7.90 | $2K | 570,602 |
| 2015-10-06 | Macdonald R. Loch Chief Scientific Officer | Conversion · Series A Convertible Preferred Stock | −25,000 | 0 | ||
| 2015-10-06 | Macdonald R. Loch Chief Scientific Officer | Conversion · Series C-1 Convertible Preferred Stock | −5,373 | 0 |
Page 16 of 18 · 346 trades